Literature DB >> 29625193

Icaritin induces ovarian cancer cell apoptosis through activation of p53 and inhibition of Akt/mTOR pathway.

Lvfen Gao1, Ming Chen2, Yuan Ouyang2, Ruobin Li2, Xian Zhang1, Xuesong Gao1, Shaoqiang Lin3, Xiaoyu Wang4.   

Abstract

AIMS: Ovarian cancer (OC) has the highest mortality rate of all gynecological cancers. Currently, the first-line OC treatment consists of cytoreductive surgery and platinum-based chemotherapy. However, most patients develop chemoresistance after the first-line treatment limits the success of treatment. Therefore, there is an urgent need to identify effective therapeutic agents. MAIN
METHODS: Cell viabilities were detected by MTS assay; Annexin V-FITC/PI assay and western blotting assay were performed to analyze the apoptotic cells in vitro; An immunofluorescence assay was performed to analyze the TUNEL+ apoptotic cells in vivo; Patient-derived xenografts were established to test the in vivo antitumor effects; The key proteins of p53, caspase-mediated apoptotic pathway and Akt/mTOR pathway were detected by Western blotting. KEY
FINDINGS: Icaritin, a prenylflavonoid derivative from Epimedium Genus, inhibited the proliferation of drug-sensitive OC cells (OV2008 and C13*) and cisplatin resistant OC cells A2780cp. Icaritin induced OC cell apoptosis in vitro, as indicated by the increase of Annexin V+/PI+ apoptotic cells analyzed with flow cytometry, and the cleavage of caspase 9, caspase 3 and poly-ADP-ribose polymerase (PARP) detected with western blotting. Icaritin also inhibited tumor growth and induced OC cells apoptosis in patient-derived xenografts, as indicated by the tumor growth delay and increase of TUNEL-positive cells in tumor tissues. The icaritin-induced OC cell apoptosis may be associated with the activation of p53 and the suppression of Akt/mTOR pathway. SIGNIFICANCE: This study sheds light on the underlying mechanisms of antitumor effect of icaritin, and warrants clinical trial for treatment of OC.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Akt; Apoptosis; Icaritin; Ovarian cancer; mTOR; p53

Mesh:

Substances:

Year:  2018        PMID: 29625193     DOI: 10.1016/j.lfs.2018.03.059

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  4 in total

1.  Identification of icaritin derivative IC2 as an SCD-1 inhibitor with anti-breast cancer properties through induction of cell apoptosis.

Authors:  Chen Yang; Yi-Yuan Jin; Jie Mei; Die Hu; Xiaoyu Jiao; Hui-Lian Che; Chun-Lei Tang; Yan Zhang; Guo-Sheng Wu
Journal:  Cancer Cell Int       Date:  2022-05-31       Impact factor: 6.429

2.  Systematic Review of Patient-Derived Xenograft Models for Preclinical Studies of Anti-Cancer Drugs in Solid Tumors.

Authors:  Yoshikatsu Koga; Atsushi Ochiai
Journal:  Cells       Date:  2019-05-06       Impact factor: 6.600

3.  Icaritin promotes apoptosis and inhibits proliferation by down-regulating AFP gene expression in hepatocellular carcinoma.

Authors:  Hui Li; Yujuan Liu; Wei Jiang; Junhui Xue; Yuning Cheng; Jiyin Wang; Ruixiang Yang; Xiaowei Zhang
Journal:  BMC Cancer       Date:  2021-03-25       Impact factor: 4.430

4.  Icaritin Inhibits Migration and Invasion of Human Ovarian Cancer Cells via the Akt/mTOR Signaling Pathway.

Authors:  Lvfen Gao; Yuan Ouyang; Ruobin Li; Xian Zhang; Xuesong Gao; Shaoqiang Lin; Xiaoyu Wang
Journal:  Front Oncol       Date:  2022-04-01       Impact factor: 5.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.